Lung,Cancer,Diagnostics,Market business, insurance Lung Cancer Diagnostics Market Is Poised To Reach $3.64 Bill

Small offices have unique needs, and thatincludes document shredding. Designed with the smaller business inmind, the Dahle 20314 is a cross-cut shredder that offers Level 3security and brings you into compliance with federal regulations. The As we all know to live in this world we have to perform some activity by which we can earn money. There are many activities by which we can earn money and meet the standards to live in this society. And from one of them is franchise.  Franc

The global lung cancer diagnostics market is expected to reach USD 3,644.6 million by 2024, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies. Browse full research report on Global Lung Cancer Diagnostics  Market: http://www.grandviewresearch.com/industry-analysis/lung-cancer-diagnostics-marketVarious biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer. Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation. Read detailed report or request for sample of this research report:                  http://www.grandviewresearch.com/industry-analysis/lung-cancer-diagnostics-market/requestFurther key findings from the study suggest:The small cell lung cancer segment accounted for around 15% market share in 2015. This is an aggressive subtype of the lung malignancies, which has proven to be fatal within a short period of time if left undiagnosed.Non-small cell lung cancer was identified as the largest segment in 2015 with revenue of over USD 1,300.0 million. This is majorly due to the availability of novel lung cancer diagnostics that facilitate the detection of large tumor growths.The imaging tests segment was identified as the largest revenue generating segment in 2015 with a market share of around 50%. Major factors responsible for the large market share include the frequent use of various imaging techniques such as CT scan, X-ray, and MRI in the detection of lung malignancies coupled with the increased availability of the diagnostic tools.The molecular testing segment is expected to grow at a profitable rate of around 10% over the forecast period. The introduction of novel molecular testing techniques coupled with the increasing number of investments to support the research and development efforts for the development of biomarker-based molecular testing in lung cancer detection is expected to foster the demand of this segment over the forecast period.In 2015, North America accounted for the largest revenue share of over 30% majorly due to supportive government policies in the region coupled with the availability of technology-enabled lung cancer diagnosticsAsia Pacific region is expected to reach a revenue share of over 28% by 2024. Major factors responsible for the growth include the constantly improving healthcare infrastructure, the growing awareness of the disease symptoms, and a wide base of unmet clinical needs in the developing countries in the region.Major players of this market include bioMérieux, Roche Diagnostics, Qiagen N.V., Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, Janssen, AstraZeneca plc, and Sanofi S.A.Novel product launches in the lung cancer diagnostics product portfolio is one of the major strategic initiatives adopted by the market players. For instance, Orion genomics is involved in the development of novel biomarkers for lung cancer diagnosis. Allegro Diagnostics is involved in the development and commercialization of pulmonary genomics-based lung cancer diagnostics. Browse more reports of this category by Grand View  Research: http://www.grandviewresearch.com/industry/clinical-diagnosticsGrand View Research has segmented the global lung cancer diagnostics market on the basis of type, test, and region:Global Lung Cancer Diagnostics Type Outlook (Revenue, USD Million, 2016 – 2024)Small Cell Lung CancerNon-small Cell Lung CancerGlobal Lung Cancer Diagnostics Test Outlook (Revenue, USD Million, 2016 – 2024)Imaging TestBiopsySputum CytologyMolecular TestOthersLung Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2016 – 2022)North AmericaU.S.CanadaEuropeRussiaGermanyAsia PacificJapanChinaLatin AmericaBrazilMEASouth AfricaRead our blogs - legalworkshop.org, grandviewresearch.com/blogs/healthcare